ArticleLife (Basel, Switzerland)2026
18F-FDG PET-CT- vs. CT-Based Radiotherapy Treatment Planning for Head and Neck Cancer.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Nutritional management and oral health-related outcomes in head and neck cancer treated with radiotherapy or chemoradiotherapy: a systematic review.BMC oral health · 2026Pooled it
- Effectiveness of radiotherapy or chemoradiotherapy in older patients with advanced-stage, non-surgically treated head and neck cancer: A machine learning analysis.Medical oncology (Northwood, London, England) · 2026Article
- Radiomics for risk stratification in brain metastases: potential in melanoma brain metastases.Clinical & experimental metastasis · 2026Article
- 3D-Printed prosthesis for recurrent femoral metastasis with periprosthetic infection: A case report.Experimental and therapeutic medicine · 2026Article
- A novel mitochondrial-related gene signature for assessing the tumor immune microenvironment and predicting prognosis in human glioma.Discover oncology · 2026Article
- Predicting Post-Radiotherapy Epigenetic Age Acceleration From Pre-Treatment Data Using a Machine Learning Framework in Head and Neck Cancer Patients.Cancer medicine · 2026Article
- Clinical Analysis of Rotational-Translational Error Coupling in 3DoF Versus 6DoF CBCT Couch Corrections:A Cross-Sectional Study.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesPrecise staging and tumor delineation are essential for optimizing treatment and enhancing outcomes of radiotherapy (RT). While computed tomography (CT)-based RT remains standard, fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) offers improved detection of primary and nodal disease. This study investigates the role of PET/CT in RT planning of HNSCC.
methodsFifty-one HNSCC patients underwent radical volumetric modulated arc RT with concurrent cisplatin chemotherapy in a prospective study. Two RT plans per patient were sequentially created by a single oncologist using CT-only and PET/CT data, respectively. Planning target volumes (PTVs) for primary and nodal regions were independently defined, and dose-volume histograms were analyzed and compared.
resultsPET/CT significantly affected TNM staging, increasing the T-stage in 11.8% of patients and the N-stage in 33.3%. Distant metastases were found in 9.8% of patients, leading to a redefinition of the overall treatment policy. PET/CT-based planning improved primary tumor PTV coverage (PTV4) in 37.2% (19/51) of cases. The tumor areas excluded from the CT-based planning received an average of 85.6% of the prescribed PTV4 dose (range 18-93%), while in PET/CT planning, they received 95.4% (range 93-99%) (
conclusionsPET/CT improves target delineation for primary tumors and lymph nodes, also allowing for dose escalation in metabolically highly active lesions in patients with HNSCC. The method also reveals occult distant metastases in a subset of patients, enabling personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.